Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Rejection of leukemic cells requires antigen-specific T cells with high functional avidity.

Vincent K, Hardy MP, Trofimov A, Laumont CM, Sriranganadane D, Hadj-Mimoune S, Salem Fourati I, Soudeyns H, Thibault P, Perreault C.

Biol Blood Marrow Transplant. 2014 Jan;20(1):37-45. doi: 10.1016/j.bbmt.2013.10.020. Epub 2013 Oct 23.

2.
3.

Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others.

Choi EY, Yoshimura Y, Christianson GJ, Sproule TJ, Malarkannan S, Shastri N, Joyce S, Roopenian DC.

J Immunol. 2001 Apr 1;166(7):4370-9.

4.

Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.

Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.

J Immunol. 2010 Sep 15;185(6):3445-55. doi: 10.4049/jimmunol.1001397. Epub 2010 Aug 23.

5.

Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.

Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, Ekkebus R, Rijal P, Celie PH, Huang JH, Emmelot ME, Spaapen RM, Lokhorst H, Schumacher TN, Mutis T, Rodenko B, Ovaa H.

J Immunol. 2014 Nov 15;193(10):4803-13. doi: 10.4049/jimmunol.1400800. Epub 2014 Oct 13.

6.
8.

Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.

Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ.

J Immunol. 2003 Sep 1;171(5):2251-61.

9.

Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone.

Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, Thomas X, Tiberghien P, Simpson E, Rigal D, Scott D.

J Immunol. 2013 Jan 1;190(1):184-94. doi: 10.4049/jimmunol.1201163. Epub 2012 Dec 7.

10.

Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

Kemp RA, Ronchese F.

J Immunol. 2001 Dec 1;167(11):6497-502.

11.
13.

Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

Watson AM, Mylin LM, Thompson MM, Schell TD.

J Immunol. 2012 Dec 15;189(12):5549-60. doi: 10.4049/jimmunol.1102221. Epub 2012 Nov 21.

14.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.

PMID:
21928126
17.

Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.

J Immunol. 1999 Jan 1;162(1):144-51.

18.
19.

Supplemental Content

Support Center